9:15 - 5:40 EDT | 6:15 - 2:40 PDT - All times are shown in EDT

08:30 am Online Registration & Virtual Coffee

8:50 am Chair’s Opening Remark

Supercharging Fundamental Knowledge in γδ T Biology to Unveil their Full Potential

9:00 am Understanding Vg9Vd2 Activation: What is Known and the Rest


• Outlining the molecular basis of Vg9Vd2 T cell activation
• Exploring the role of Vg9Vd2 in cancer settings
• Discussing questions regarding regulation

9:30 am Panel Discussion: Comparing the Activities of Different γδ T Subsets: Which one is best?

  • Oliver Nussbaumer VP of Immunology, GammaDelta Therapeutics
  • Jonathan Fisher NIHR Clinical Lecturer & GOSH Charity Springboard Fellow , UCL-GOS Institute of Child Health & Great Ormond Street Hospital
  • Brian Philip Associate Director of Allogeneic Development, Triumvira Immunologics


• Outlining the advantages of the γδ 2 subset and their response to phosphoantigens
• Discussing the issues of repeated antigen stimulation with delta 2 and loss of response
• Exploring the potential of the tissue resident delta 1 subset to treat solid tumors

10:00 am Virtual Speed Networking & Morning Break


Reinventing the face-to-face networking in the virtual world. We will pair you up with fellow attendees to break the ice and make new and lasting connections!

Utilizing Innovative Pre-Clinical Models to Maximize Translation into Clinical Trials

11:30 am Leveraging Immune Repertoire Sequencing to Monitor Gamma Delta T cells

  • Ned Sherry Research and Business Development, Adaptive Biotechnologies


Learn about Adaptive Biotechnologies’ immunoSEQ® Technology, an
end-to-end immunosequencing solution, and how it can help you propel
your research from experimental design to publication-ready data

• Discuss studies and applications of large-scale immunosequencing of
Gamma/Delta T cells in the field of oncology research

• How the immunoSEQ Assay can be leveraged to study drug candidate
selection, optimize dosing, determine smart drug combinations, select
biomarker endpoints, and optimize subject selection for clinical trial research.

• immunoSEQ is for Research Use Only. Not for use in diagnostic procedures

12:00 pm Of Mice and Men – Biomimetic Pre-Clinical Modelling of γδT Cell Product Efficacy

  • Jonathan Fisher NIHR Clinical Lecturer & GOSH Charity Springboard Fellow , UCL-GOS Institute of Child Health & Great Ormond Street Hospital


• 3D organoid cultures
• Multi-parametric, concurrent analysis of tumour targets and T cell effectors

12:30 pm ImmunoTox: Modifying Solid Tumors to Enhance the Gamma Delta T cell Response


• Lentivirus vector modification increases tumor cytotoxicity among Vg9Vd2 T cells
• Complex viral vectors both stimulate and support tumor killing
• Potent tumor destruction is driven by local stimulation that drives tumor infiltration by Vg9Vd2 T cells

1:00 pm Lunch & Networking

Exploring Antibody-Based Approaches for γδ T Activation

2:30 pm Bispecific Antibodies to Engage Vγ9Vδ2-T cells for Cancer Immunotherapy


• Introduction to Vγ9Vδ2-T cells; a unique T cell subset with characteristics that make them well suited for a T cell engager approach.
• The broad anticancer potential of tumor targeted activation of Vγ9Vδ2-T cells using a bispecific antibody approach is illustrated in various settings

3:00 pm Targeting Immunosuppressive γδ1 Tcells in Cancer and Synergies with Other γδ Centric Therapies


• γδ1 T cells with immunosuppressive (IS) properties as therapeutic targets in solid tumors: why and how?
• First in class IS γδ1 T cell targeting monoclonal antibody (LYT-210): development and properties
• How should we be thinking in designing clinical trials in the γδ T cells context: are companion diagnostics a must have?

3:30 pm Afternoon Break & Poster Session

Exploring Antibody-Based Approaches for γδ T Activation

4:00 pm Panel Discussion – Leveraging Antibody-Based Approaches to Engage Gamma Delta T Cells

4:30 pm Next-Generation Immunotherpeutics – Selective Recruitment of γδ T Cells by Bispecific Antibodies


• Immunotherapeutic approaches for redirecting pan CD3+ T cells to target cancer is under clinical investigation
• Prototypic bispecific antibody concurrently binds to the Vγ9 chain of the Vγ9Vδ2+γδT cells and to tumor antigens for efficient lysis of tumor cells (in vitro and in vivo).
• Bispecific antibodies selectively activates Vγ9+ γδ T cells and recruits γδT cells into cell-cell conjugate formation with tumor cells.

5:00 pm Chairman’s Closing Remarks & Close of Day 1

POST EVENT CONTENT: Maximizing the Clinical Potential of Gamma Delta T Cell-Based Therapies


• Overview of manufacture of gene-modified gamma delta T cells
• Understanding and optimizing activation pathways in gamma delta T cells
• Optimizing the health and persistence of gamma delta T cell therapies and minimizing host versus graft responses